Lipocine Stock Price. Everything You Need To Know About The Lipocine Stock!
Lipocine, Inc. is a clinical-stage biopharmaceutical company headquartered in Salt Lake City, Utah, that specializes in the research and development of delivery technologies for drugs. The company went IPO on March 21, 2014, and currently employs 17 full-time employees.
Lipocine, Inc. is primarily focused on leveraging its Lip’ral platform to develop differentiated products through oral delivery. The company has a portfolio of differentiated product candidates that target high unmet needs for neurological and psychiatric Central Nervous System (CNS) disorders, liver diseases, and hormone supplementation for men and women.
One of the firm’s product candidates, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). The company’s clinical development pipeline candidates include LPCN 1154 for postpartum depression (PPD), LPCN 2101 for epilepsy, and LPCN 1148, an androgen therapy for the management of cirrhosis.
The company is actively exploring partnering opportunities for LPCN 1107, its candidate for the prevention of preterm birth, LPCN 1148, for the management of decompensated cirrhosis, LPCN 1144, its candidate for the treatment of non-cirrhotic NASH, and LPCN 1111.
Investing in stocks like Lipocine, Inc. can be a potentially lucrative opportunity, but it’s essential to keep in mind that investing in the pharmaceutical industry carries significant risks. Before investing, it’s crucial to conduct thorough research and understand the company’s competitors, potential for growth, and any potential risks or challenges. By monitoring key metrics like stock price and market cap, you can make informed investment decisions and potentially achieve greater returns over time.
Lipocine Stock Price. Everything You Need To Know About The Lipocine Stock! performance
- Employees 17
- Company HQ Salt Lake City
- Website https://www.lipocine.com/
- LPCN Asset Type Common Stock
- LPCN Market Capitalization 25.7M
- Earnings Per Share -3.14
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in US stocks? Look no further than Lipocine, a promising stock in the healthcare sector. Lipocine is a pharmaceutical company dedicated to developing innovative therapies for patients in need. With a focus on oral drug delivery, Lipocine is at the forefront of research and development, producing products that are not only effective but also easy for patients to consume. To invest in Lipocine from Malaysia, Thailand, Indonesia, or Vietnam, you can use the Zorion investment platform. Zorion provides insights and recommendations to help you make informed decisions about your investments. With our user-friendly platform, you can easily access resources and educational materials to further enhance your investment knowledge. Don’t miss out on the opportunity to invest in Lipocine and be a part of transforming healthcare. Start investing with Zorion today!
